KRAS Kickers featured at AACR

Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC

Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer

Lilly Announces Details of Presentations at 2021 American Association for Cancer Research

Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial

The Epic Battle with Cancer's 'Death Star'

How Scientists Shot Down Cancer’s ‘Death Star’

Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations

The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer